Literature DB >> 12096275

The effect of endothelial cell overexpression of plasminogen activator inhibitor-1 on smooth muscle cell migration.

Richard R Proia1, Peter R Nelson, Mary Jo Mulligan-Kehoe, Robert J Wagner, Arthur J Kehas, Richard J Powell.   

Abstract

INTRODUCTION: Plasminogen activator inhibitor-1 (PAI-1), a known inhibitor of plasminogen activators, may regulate smooth muscle cell migration (SMC) through alteration in matrix metalloproteinase (MMP) activity.
METHODS: To study the effect of endothelial cell (EC) PAI-1 overexpression on SMC migration, RT-PCR was used to clone the full length PAI-1 gene, which was ligated into the pCMV/myc/ER expression vector. With electroporation, bovine aortic ECs were transfected with either the PAI-1 construct or the empty vector as control. EC PAI-1 overexpression was shown with a specific PAI-1 activity assay and enzyme-linked immunosorbent assay. The effect of EC PAI-1 overexpression on SMC migration was measured with a modified Boyden-chamber assay. SMC MMP expression was measured with zymography.
RESULTS: Selected clones (EC9, EC21) had a three-fold to five-fold increase in PAI-1 activity compared with untransfected EC and empty vector EC (ECC). Similarly, enzyme-linked immunosorbent assay results showed a 3.5-fold to 5.5-fold increase in PAI-1 levels in EC9 and EC21 versus ECC. Untransfected EC and ECC had similar effects on SMC migratory patterns. Migration of SMC exposed to PAI-1 overexpressing EC was inhibited by 35% to 57% compared with ECC. This inhibitory effect was reversed with addition of exogenous urokinase-type plasminogen activator (uPA). Zymography showed downregulation of MMP-2 and MMP-9 in SMCs exposed to PAI-1 overexpressing EC.
CONCLUSION: PAI-1 overexpression with transfected EC inhibits SMC migration. This effect may be mediated through decreased SMC MMP activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096275     DOI: 10.1067/mva.2002.123687

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

Review 2.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

3.  Renal fibrosis: not just PAI-1 in the sky.

Authors:  Agnes B Fogo
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 4.  PAI-1 and kidney fibrosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.